MainStreet Investment Advisors LLC Sells 3,765 Shares of Pfizer Inc. $PFE

MainStreet Investment Advisors LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 112,814 shares of the biopharmaceutical company’s stock after selling 3,765 shares during the quarter. MainStreet Investment Advisors LLC’s holdings in Pfizer were worth $2,735,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Westbourne Investments Inc. acquired a new position in Pfizer in the first quarter valued at approximately $2,411,000. Bourne Lent Asset Management Inc. increased its stake in shares of Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock valued at $927,000 after acquiring an additional 18,200 shares in the last quarter. Strs Ohio bought a new stake in shares of Pfizer in the 1st quarter valued at $49,968,000. IFM Investors Pty Ltd boosted its stake in Pfizer by 3.8% during the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock worth $27,322,000 after acquiring an additional 41,263 shares in the last quarter. Finally, Intrua Financial LLC grew its holdings in Pfizer by 17.4% in the first quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company’s stock worth $1,986,000 after purchasing an additional 11,643 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.06 on Tuesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock has a market cap of $142.47 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The stock’s fifty day simple moving average is $24.81 and its two-hundred day simple moving average is $24.45.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.